

# Curriculum Vitae

---

Update 4-1-2009

## Charlie Strange, M.D.

### Present Position

Professor of Pulmonary and Critical Care Medicine  
Medical University of South Carolina  
96 Jonathan Lucas Street, 812 CSB  
Charleston, SC, 29425-0630  
(843)792-3712 Fax (843) 792-0732  
E-mail: strangec@musc.edu

### Major Interests

Alpha-1-Antitrypsin Deficiency/ Chronic Obstructive Pulmonary Disease  
Scleroderma and Interstitial Lung Disease  
Pulmonary Hypertension

### Education

Davidson College, Davidson, N.C., B.S., 1978.  
Medical College of Virginia, M.D., 1982.  
Internal Medicine Internship and Residency,  
Medical University of South Carolina, 1982-1985.  
Fellow, Division of Pulmonary and Critical Care Medicine,  
Medical University of South Carolina, 1985-1987.  
Instructor in Medicine, Division of Pulmonary and Critical Care Medicine,  
MUSC, 1987-1988.  
Assistant Professor, Division of Pulmonary and Critical Care Medicine,  
MUSC, 1988- 1993.  
Associate Professor, Division of Pulmonary and Critical Care Medicine, MUSC, 1993-  
2004, with Tenure 1998.  
Professor of Medicine, Division of Pulmonary and Critical Care Medicine, MUSC 2004  
Graduate Faculty, Molecular and Cellular Biology and Pathobiology, MUSC, 1994-2001.  
Graduate Faculty, College of Graduate Studies, MUSC, 2002- Present

### Board Certification

American Board of Internal Medicine, September 11, 1985  
Subspecialty Boards in Pulmonary Medicine, November, 1988  
Subspecialty Boards in Critical Care Medicine, 1989, Recertification March 2000

### Society Membership

Sigma Pi Sigma Honorary Physics Society  
American Thoracic Society  
American College of Chest Physicians, Fellow 1989

### Professional Activities

1987- Present MUSC Department of Medicine Intern Recruitment Committee

1990- 2002	Director Medical Intensive Care Unit, MUSC
1991- Present	Director, Pulmonary Function Laboratory, MUSC
1993- Present	Lecturer, Pulmonary Physiology, MUSC School of Medicine
1994- 1998	South Carolina Governor, American College of Chest Physicians
1995- Present	Admissions interviewer, MUSC College of Medicine
1996- 2000	Member, Institutional Review Board for Human Research
1997- Present	Member, SC Medicare Carrier Advisory Committee
1998-1999	Chair, Clinical Pulmonary Section, American College of Chest Physicians
1998- 1999	Chairman, Council of Governors, Member Board of Regents, American College of Chest Physicians
1999- Present	Alpha-1 Foundation Medical and Scientific Advisory Committee, Chair 2005-2007
2000-2003	Chair, ACCP Web Oversight Committee
2001-2005	Critical Care Relevance Reviewer, American Board of Internal Medicine
2001-Present	Program Committee, Clinical Problems Assembly, American Thoracic Society
2002-2004	Chair, ACCP Interstitial Lung Disease Network
2004-2005	Chair, Program Committee, Clinical Problems Assembly, American Thoracic Society
2003-Present	Faculty of 1000 Medicine Project
2003- 2005	Editorial Consultant, Physicians' Information and Educational Resource (PIER), American College of Physicians
2006- Present	Board of Directors, Waring Historical Library, Medical University of SC
2006- Present	ACCP Scientific Presentations and Awards Committee
2007	Co-Chairman Alpha-1 Foundation International Conference "New Insights into the Biology of AAT: The Expanded role of AAT in the Treatment of AAT Deficient individuals and Other Diseases"
2007	UHC Rapid Rescue Project
2007-Present	Chest Foundation Board of Directors

## **Current Research Support (partial listing)**

2001-2010	PI-Alpha-1 Foundation Registry, Alpha Coded Testing Study – Alpha-1 Foundation
2004- 2009	Co-Investigator Rare Lung Disease Clinical Research Network (1 U54 RR019498-01), PI: Trapnell, Bruce.
2007-2010	PI- Biologic Lung Volume Reduction in Severe Upper Lobe Predominant Emphysema, Aeris Therapeutics, Inc.
2008-20112	Co-Investigator, Scleroderma Lung Study II. (PI Don Tashkin) NIH/NHLBI/NIAMS

## **Recent Honors**

Best Doctors in America, 2003-2008: General Pulmonary and Critical Care Medicine, Interstitial Lung Diseases, Chronic Obstructive Pulmonary Disease  
America's Top Physicians 2004-2006, Consumers Research Council of America  
Who's Who in Medicine and Healthcare 2006-8.  
First Runner Up, Medical Jeopardy, AOA Chapter, 1999; Second Runner Up 2008.  
MUSC Medical Student Faculty Excellence Award nominee- 2006  
Distinguished Service Award 2007- Chest Foundation  
Community Service Award 2008- Alpha-1 Association

## **Editorial Board**

Case Reports in Medicine

### **Consultant to the Editorial Board**

American Review of Respiratory and Critical  
Care Medicine

Chest

Clinical Genetics

Clinical Immunology and Immunopathology

European Respiratory Journal

International Archives of Allergy and  
Immunology

The International Journal of Biochemistry &  
Cell Biology

International Journal of Tuberculosis and Lung  
Disease

Journal of the American Academy of Dermatology

Journal of the American College of  
Cardiology

Journal of Arthritis and Rheumatism

Journal of Critical Illness

Journal of Respiratory Diseases

Journal of Speech, Language, and  
Hearing Research

Lung

Mayo Clinic Proceedings

Respiration

Respiratory Care

Thorax

## **Bibliography**

### **Papers**

1. Strange C, Heffner JE, Collins BS, Brown FM, Sahn SA. Pulmonary hemorrhage and air embolism complicating transbronchial biopsy in pulmonary amyloidosis. Chest 1986; 92:367-9.
2. Strange C, Barbarash R, Heffner JE. Lidocaine concentrations in bronchoscopic specimens. Chest 1988; 93:547-49.
3. Lorch DG, Wooten S, Gordon L, Cooper JF, Strange C, Sahn SA. The effect of patient positioning on the distribution of tetracycline in the pleural space during pleurodesis. Chest 1988; 93:527-29.
4. Strange C, Allen ML, Friedland P, Cunningham J, Sahn SA. Biliopleural fistula: A complication of percutaneous biliary drainage. Am Rev Respir Dis 1988; 137(4):959-61.
5. Heffner JE, Strange C, Sahn SA. The impact of respiratory failure on the diagnosis of tuberculosis. Arch Intern Med 1988; 148:1103-8.
6. Wooten SA, Barbarash RA, Strange C, Sahn SA. Systemic absorption of tetracycline and lidocaine following intrapleural instillation. Chest 1988; 94(5):960-63.
7. Strange C, Tomlinson JR, Wilson C, Harley R, Miller KS, Sahn SA. The histology of experimental pleural

- injury with tetracycline, empyema, and carrageenan. *Experimental and Molecular Path* 1989; 51:205-19.
8. Strange C, Halstead L, Baumann M, Sahn SA. Subglottic Stenosis in Wegener's Granulomatosis: Development During Cyclophosphamide with Response to CO<sub>2</sub> Laser Therapy. *Thorax* 1990; 45:300-1.
  9. Baumann M, Strange C, Sahn SA. The value of the chest radiograph in the assessment of relapse during corticosteroid withdrawal in sarcoidosis. *AJR* 1990; 154:481-5.
  10. Scott TF, Goust JM, Strange C, Brillman J. Systemic lupus erythematosus, thrombocytopenia, and human T-lymphotrophic virus, type I (HTLV-I). *J Rheumatol* 1990; 17:1565-6.
  11. Sudduth CD, Cambell B, Strange C, Sahn SA. Metastatic choriocarcinoma of the lung presenting as hemothorax. *Chest* 1991; 99:527-8.
  12. Strange C, Nicolau DP, Dryzer SR. Chylous transport of amiodarone. *Chest* 1992; 101:573-4.
  13. Polos PG, Wolfe D, Harley RA, Strange C, Sahn SA. Pulmonary hypertension and human immunodeficiency virus infection; two reports and a review of the literature. *Chest* 1992; 101:474-8.
  14. Nicolau DP, Uber WE, Crumbley AJ, Strange C. Amiodarone - cyclosporine interaction in an orthotopic cardiac transplant patient. *J Heart Lung Transplant* 1992; 11:564-8.
  15. Ludwicka A, Trojanowska M, Smith EA, Baumann M, Strange C, Korn JH, Piela T, LeRoy EC, Silver RM. Growth and characterization of fibroblasts obtained from bronchoalveolar lavage of scleroderma patients. *J Rheumatol* 1992; 19:1716-23.
  16. Joseph J, Viney S, Beck P, Strange C, Sahn SA, Basran G. Amylase isoenzyme analysis in the differential diagnosis of amylase rich pleural effusions. *Chest* 1992, 102: 1455-9.
  17. Baumann M, Heinrich K, Sahn SA, Strange C. Pleural macrophages differentially alter mesothelial cell growth and collagen production. *Inflammation* 1993, 17:1-12.
  18. Strange C, Sahn SA. The clinician's perspective on parapneumonic effusions and empyema. *Chest* 1993, 103:259-61.
  19. Silver RM, Warrick JH, Kinsella MB, Staudt LS, Baumann MH, Strange C. Cyclophosphamide and low dose prednisone therapy in systemic sclerosis (scleroderma) patients with interstitial lung disease. *J Rheumatol* 1993; 20:838-44.
  20. Joseph J, Strange C, Sahn SA. The spectrum of pleural effusions in hospitalized AIDS patients. *Ann Intern Med* 1993, 118:856-9.
  21. Strange C, Allen ML, Harley R, Lazarchick J, Sahn SA. Intrapleural streptokinase in experimental empyema. *Am Rev Respir Dis* 1993; 147:962-966.
  22. Sudduth CD, Strange C, Cook WR, Miller KS, Silver RM, Baumann M, Collop NA, LeRoy EC. Failure of the circulatory system limits exercise performance in patients with systemic sclerosis. *Am J Med* 1993; 95:413-8.
  23. Dryzer SR, Joseph J, Baumann MH, Birmingham K, Sahn SA, Strange C. Early inflammatory response of minocycline and tetracycline on the rabbit pleura. *Chest* 1993; 104:1585-8.
  24. Dryzer SR, Allen ML, Strange C, Sahn SA. A comparison of rotation and nonrotation in tetracycline pleurodesis. *Chest* 1993; 104:1763-6.
  25. Baumann M, Heinrich K, Sahn SA, Green C, Harley R, Strange C. An electron microscopic analysis of the normal and activated pleural macrophage. *Exp Lung Research* 1993, 19:731-42.
  26. Ohba T, McDonald JK, Silver RM, Strange C, LeRoy EC, Ludwicka A. Scleroderma bronchoalveolar lavage fluid contains thrombin, a mediator of human lung fibroblast proliferation via induction of platelet-derived growth factor  $\alpha$ -receptor. *Am J Respir Cell Mol Biol* 1994; 10:405-12.
  27. Kennedy L, Rusch V, Strange C, Ginsberg RA, Sahn SA. Pleurodesis using talc slurry. *Chest* 1994; 106:342-6.
  28. LeMense GP, Strange C. Granulomatous pneumonitis following intravesical BCG: what therapy is needed? *Chest* 1994; 106:1624-6.
  29. Strange C, Baumann MH, Sahn SA, Idell SA. Effects of heparin or urokinase on the resolution of tetracycline-induced pleural disease. *Am J Respir Crit Care Med* 1995; 151:508-15.31.
  30. Birmingham K, Vaughan LM, Strange C. Rapid serum minocycline assay for pleurodesis monitoring using high performance liquid chromatography with radial compression. *Therapeutic Drug Monitoring* 1995; 17:268-72.
  31. Lemense G, Strange C, Reid C, Sahn SA. Empyema thoracis: Therapeutic management and outcome.

- Chest 1995; 107:1532-7.
32. Kennedy L, Harley R, Sahn SA, Strange C. Talc slurry pleurodesis: pleural fluid and histologic analysis. Chest 1995; 107:1707-12.
  33. Ludwicka A, Strange C, Smith E, Leroy EC, Silver R. Transforming growth factor beta in bronchoalveolar lavage of patients with systemic sclerosis. J Rheumatol 1995; 22:1876-83.
  34. Baumann MH, Strange C, Sahn SA, Kinasewitz GT. Pleural macrophages differentially alter pleural mesothelial cell glycosaminoglycan production. Exp Lung Research 1996; 22:101-11.
  35. Strange C, Gottehrer A, Birmingham K, Heffner JE. Platelets attenuate oxidant-induced permeability in endothelial cell monolayers: glutathione dependent mechanisms. J Applied Physiol 1996; 81(4):1701-6.
  36. Retalis P, Strange C. The spectrum of adult adenovirus pneumonia. Chest 1996, 109:1656-7.
  37. Uflacker R, Strange C, Vujic I. Massive pulmonary embolism: preliminary results of treatment with the amplatz thrombectomy device. J Vasc Interventional Radiology 1996, 7:519-28.
  38. Bolster MB, Ludwicka A, Sutherland S, Strange C, Silver RM. Cytokine secretions in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum 1997, 40:743-751.
  39. Baumann MH, Strange C. The clinicians's perspective on pneumothorax management. Chest 1997; 112: 822-8.
  40. Baumann MH, Strange C. Spontaneous pneumothorax: a more aggressive approach? Chest 1997; 112:789-804.
  41. Strange C, Vaughan L, Franklin C, Johnson J. Comparison of train of four monitoring and clinical assessment during continuous infusion neuromuscular blockade. Am Rev Respir Crit Care Med 1997; 156:1556-61.
  42. Judson MA, Strange C. Bullous sarcoidosis: a report of three cases. Chest 1998, 114:1474-7.
  43. Ozgun EM, Strange C, Silvestri GA. The impact of a standardized protocol for placement of indwelling arterial catheters. Respir Care, 1999; 44:1193-7.
  44. Strange C, Bolster M, Mazur J, Taylor M, Gossage JR, Silver R. Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension. Chest 2000, 118:1077-82.
  45. Hunninghake GW, Zimmerman MB, Schwartz DA, King TE, Lynch J, Hegele R, Waldron J, Colby T, Muller N, Lynch D, Galvin J, Gross B, Hogg J, Toews G, Helmers R, Cooper JAD, Baughman R, Strange C, Millard M. Utility of a lung biopsy for the diagnosis of IPF. Am J Respir Crit Care Med 2001, 164(2):193-6.
  46. Avendano CE, Flume PA, Baliga P, Lewin DN, Strange C, Reuben A. Hepatopulmonary syndrome occurring after orthotopic liver transplantation. Liver Transpl 2001; 7: 1081-1084.
  47. Baumann, MH, Strange C, Heffner JE, Light R, Kirby TJ, Klein J, Luketich JD, Panacek EA, Sahn SA. Management of spontaneous pneumothorax: an American College of Chest Physicians delphi consensus statement. Chest 2001; 119(2): 590-602.
  48. Strange C, Wilner I. Alpha-1 Foundation Research Registry: from the past to the future. J Ped Gastro and Nutrition 2002; 34:1.
  49. Loveland SM, Lewin JJ, Mazur J, Strange, C. Obese male treated with drotrecogin alpha (activated). Annals of Phamacotherapy 2003; 37:918-9.
  50. Doelken P, Strange C. Chest ultrasound for "Dummies". Chest. 2003; 123:332-3.
  51. Highland KB, Strange C, Heffner JE. Long term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary diseases: a meta-analysis. Ann Intern Med 2003, 138(12):969-73.
  52. Highland KB, Strange C, Mazur J, Simpson KN. Treatment of pulmonary arterial hypertension: a decision analysis. Chest 2003; 124:2087-92.
  53. Alpha<sub>1</sub>-Antitrypsin Deficiency Task Force. Standards for the diagnosis and management of individuals with alpha<sub>1</sub>-antitrypsin (AAT) deficiency. Am J Respir Crit Care Med 2003, 168:818-900.
  54. Strange C. Top ten list in interstitial lung disease. Chest 2004; 125:272-4.
  55. Afrin L, Greenland J, Brown A, Frankis M, Strange C. Telemedicine-based access to second opinions for the elderly. Medinfo 2004, 2004 (CD):1500.
  56. Fanos JH, Strange C. "The lion, the witch, and the wardrobe": impact of siblings of individuals with AAT deficiency. American J Medical Genetics 2004, 130(3):251-7.
  57. Strange C, Dickson M, Carter C, Carpenter MJ, Holladay, Lundquist R, Brantly ML. Genetic testing for

- alpha<sub>1</sub>-antitrypsin deficiency. *Genet Med* 2004, 6: 204-10.
58. Afrin L, Greenland J, Brown A, Frankis M, Strange C, Kurent J. Telemedicine-based second opinions for the elderly. *Telemedicine and e-Health* 2005 Apr; 11(2): 242.
  59. Stoller JK, Tomaszewski J, Crystal RG, Arroliga A, Strange C, Killian DN, Schluchter MD, Wiedemann HP for the Alpha 1-Antitrypsin Deficiency Registry Study Group. The rate and causes of death among individuals with severe deficiency of alpha 1-antitrypsin: finding from the National Heart, Lung, and Blood Institute registry for patients with severe deficiency of alpha -1 antitrypsin, *Chest* 2005,127(4):1196-204.
  60. Bowlus C, Strange C, Willner I, Reuben A, Xie L, Woolson R, Holladay B. Factors associated with advanced liver disease in adults with alpha1-antitrypsin deficiency. *Clinical Gastroenterology and Hepatology* 2005, 3(4):390-6.
  61. Stoller JK, Sandhaus RA, Turino G, Dickson R, Rodgers K, Strange C. Delay in diagnosis of alpha-1 antitrypsin deficiency: A Continuing Problem, *Chest* 2005, 128:1989-94.
  62. Flume PA, Strange C, Ye X, Ebeling M, Hulsey T, Clark LL. Pneumothorax in cystic fibrosis. *Chest* 2005, 128:720-8.
  63. Silvestri G, Strange C. Rest in Peace: The decline in training and use of the closed pleural biopsy. *J Bronchology* 2005; 12:131-2.
  64. Strange C. Treatment for secondary pulmonary hypertension. *Chest*. 2005; 128(4):1897-8.
  65. Strange C, Highland KB. Pulmonary hypertension in interstitial lung disease. *Curr Opin Pulm Med* 2005; 11:452-5.
  66. Strange C. The rise and fall of pleural ultrasound. *J Bronchol* 2005, 12 (4):191-2.
  67. Strange C, Stoller JK, Sandhaus RA, Turino G, Dickson R. Results of a survey of patients with alpha-1 antitrypsin deficiency. *Respiration* 2006, 73(2):185-90.
  68. Stocks JM, Brantly M, Barker A, Kueppers F, Strange C, Donohue JF, Sandhaus R. Multi-center study: the biochemical efficacy, safety and tolerability of a new alpha-1-proteinase inhibitor, Zemaira. *Journal of COPD*, 2006,3:17-23.
  69. Strange C, Moseley MA, Jones Y, Schwarz L, Xie L, Brantly ML. Genetic testing of minors for alpha-1 antitrypsin deficiency, *Arch Pediatr Adolesc Med* 2006, 160:531-4.
  70. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, the Scleroderma Lung Study Research Group. Cyclophosphamide versus Placebo in Scleroderma Lung Disease. *N Engl J Med* 2006; 354:2655-2666.
  71. Eden E, Holliday B, Xie L, Strange C. Asthma and allergy in alpha-1 antitrypsin deficiency. *Respiratory Medicine*, 2006; 100(8):1384-91.
  72. Clayton SB, Mazur JE, Condren S, Hermayer K, Strange C. Evaluation of an intensive insulin protocol in a medical intensive care unit. *Crit Care Med*, 2006, 34:2974-8.
  73. Carpenter MJ, Strange C, Jones Y, Dickson MR, Carter C, Moseley MA, Gilbert GE. Does genetic testing result in behavioral health change? Changes in smoking behavior following testing for Alpha-1 Antitrypsin Deficiency. *Ann Behav Med*, 2007, 33(1):22-28.
  74. Khanna D, Yan X, Tashkin DP, Furst DE, Elashoff R, Roth MD, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel D, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly K, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Clements PJ for the Scleroderma Lung Study Group. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease- results from the Scleroderma Lung Study. *Arthritis Rheum* 2007, 56, 5: 1676–1684. PMID: 17469162
  75. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, the Scleroderma Lung Study Research Group. Effects of 1-Year Treatment with

- Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease. *Am J Respir Crit Care Med* 2007; epub, 2008, 176:1026-34. PMID: 17717203
76. DeMeo DL, Sandhaus RA, Barker AF, Brantly ML, Edward Eden E, McElvaney NG, Rennard S, Burchard E, Stocks JM, Stoller JK, Strange C, Turino GM, Campbell EJ, Silverman EK. Determinants of airflow obstruction in severe alpha 1-antitrypsin deficiency. *Thorax* 2007; 62(9):806-13. PMID: 17389752
  77. Strange C, Herth FJF, Kovitz KL, McLennan G, Ernst A, Goldin J, Noppen M, Criner GJ, Sciruba FC, and the VENT Study Group. Design of the Endobronchial Valve for Emphysema Palliation Trial (VENT): a non-surgical method of lung volume reduction. *BMC Pulmonary Medicine* 2007, 7:10. <http://www.biomedcentral.com/1471-2466/7/10> PMID: 17711594
  78. Strange C, Bolster MB, Silver RM, Roth M, Theodore A, Goldin J, Clements P, Chung J, Elashoff RM, Suh R, Smith EA, Tashkin DP and the Scleroderma Lung Study Research Group. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. *Am J Respir Crit Care Med*, 2008; 177(1): 91-8. PMID: 17901414
  79. Stoller JK, Fromer L, Brantly M, Stocks J, Strange C. Primary care diagnosis of alpha-1 antitrypsin deficiency: issues and opportunities. *Cleveland Clinic J Med* 2007, 74:869-74. PMID: 18183837
  80. DeMeo DL, Campbell EJ, Barker AF, Brantly ML, Edward Eden E, McElvaney NG, Rennard S, Sandhaus RA, Stocks JM, Stoller JK, Strange C, Turino GM, , Silverman EK. IL10 polymorphisms are associated with airflow obstruction in severe alpha 1-antitrypsin deficiency. *Am J Respir Cell Mol Biol*; 2008, 38:114-20. PMID: 17690329
  81. Kalluri M, Huggins JT, Strange C. A 56-year-old woman with arm pain, dyspnea, and an elevated diaphragm. *Chest* 2008; 133(1):296-9. PMID: 18187758
  82. Osorio J, Watkins JM, Strange C, Jenrette JM. Radiation therapy for palliation of Eisenmenger's-associated painful splenomegaly. *Radiat Med* 2008, 26(2):84-7. PMID: 18301984
  83. Benza RL, Barst RJ, Galie N, Frost A, Lawrence EC, Langleben D, Girgis RE, Highland KB, Strange C, Black CM, Badesch DB, Rubin L, Fleming T, Naeije R. Sitaxsentan for the Treatment of Pulmonary Arterial Hypertension: A One Year, Prospective, Open Label, Observation of Outcome and Survival. *Chest* 2008; 134(4):775-82, epub Jul 14. PMID: 18625676.
  84. Sandhaus RA, Turino G, Stocks J, Strange C, Trapnell BC, Silverman EK, Everett SE, Stoller JK; Medical and Scientific Advisory Committee of the Alpha-1 Foundation. Alpha1-Antitrypsin augmentation therapy for PI\**MZ* heterozygotes: a cautionary note. *Chest*. 2008; 134(4):831-4. PMID: 18842915
  85. Dickson MR, Carter CL, Carpenter MJ, McClure R, McGee D, Zapka J, Strange C. Barriers to Genetic Testing among Persons at Risk for Alpha-1 Antitrypsin Deficiency. *Genetic Testing* 2008; 12(4):501-5. PMID: 19072562
  86. Demeo DL, Campbell EJ, Brantly ML, Barker AF, Eden E, McElvaney NG, Rennard SI, Stocks JM, Stoller JK, Strange C, Turino G, Sandhaus RA, Silverman EK. Heritability of Lung Function in Severe Alpha-1 Antitrypsin Deficiency. *Hum Hered* 2009; 67(1):38-45; PMID: 18931508
  87. Criner GJ, Pinto-Plata V, Strange C, Dransfield M, Gotfried M, Leeds W , McLennan G, Refaely Y, Tewari S, Krasna M, Celli B. Biologic Lung Volume Reduction (BioLVR) In Advanced Upper Lobe Emphysema: Phase 2 Results. *Am J Respir Crit Care Med* 2009, epub PMID: 19179484.
  88. Castaldi PJ, DeMeo DL, Kent DM, Campbell EJ, Barker AF, Brantly ML, Eden E, McElvaney NG, Rennard SI, Stocks JM, Stoller JK, Strange C, Turino G, Sanhaus RA, Griffith JL, Silverman EK. Development of Predictive Models for Airflow Obstruction in Alpha-1 Antitrypsin Deficiency. *Am J Respir Crit Care Med*, submitted.
  89. Garin MC, Highland KB, Silver RM, Strange C. Limitations to the six-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma. *J Rheum* 2009, 36(2):330-6. PMID: 19208563
  90. Garin MC, Silver RM, Simpson KN, Woolson RF, Strange C, Highland KB. Responsiveness of health-related quality of life questionnaires in pulmonary arterial hypertension. *Respiration*, 2008, submitted.

## Book and Computer Chapters

1. Strange C. Double lumen endotracheal tubes. In Heffner JE (ed): *Clinics in Chest Medicine*, WB Saunders

- 1991:497-506.
2. Strange C, Sahn SA. Management of parapneumonic pleural effusions and empyema. In Wallace RJ (ed): Infectious Disease Clinics of North America, WB Saunders 1991: 539-59.
  3. Strange C, Sahn SA. Massive hemoptysis. In Parrillo JE, Bone RC (eds) Critical Care Medicine: Principles of Diagnosis and Management, Mosby-Year Book, 1995:811-29.
  4. Strange C, Sahn SA. Massive hemoptysis. In Bone RC (ed) Pulmonary and Critical Care Medicine, Mosby-Year Book, 1995; R-19:1-11.
  5. Strange C. Hemothorax. In Antony V (ed), Seminars in Respir Med 1995; 16:324-32.
  6. Strange C. Pathogenesis and management of parapneumonic effusions and empyema. UpToDate™ CD ROM, 1995, Update 1996-2006 .
  7. Strange C. The pleura. in Stoller JA, Scanlan C, Wilkins R eds. Egan's Fundamentals of Respiratory Care. 7th ed. Mosby-Year Book, Inc., Chicago, 1997.
  8. Strange C. A patient with thrombocytopenia and renal failure. In Sahn SA, Heffner JE (eds) Critical Care Pearls II, Hanley and Belfus, Inc. 1997.
  9. Strange C. Peripheral Neuromuscular Function. in Tobin MJ. Principles and Practice of Intensive Care Monitoring. McGraw-Hill Companies, New York, 1998, 1047-55.
  10. Strange C, Sahn SA. Definitions and epidemiology of pleural space infection. In Heffner J, Sahn SA (eds), Seminars in Resp Infections. W.B.Saunders Co, Philadelphia, 1999; 14:3-8.
  11. Strange C. The lung in rare connective tissue diseases. In Strange C (ed), Seminars in Respiratory and Critical Care Medicine 1999; 20:91-98.
  12. Strange C. Guest editor. "Connective Tissue Disorders" in Lynch JP (ed), Seminars in Respiratory and Critical Care Medicine 1999; 20 (2), Thieme, NY.
  13. Strange C. Pleural complications in the ICU. In Arroliga AC (ed), Clinics in Chest Medicine, W.B. Saunders Co, 1999; 20(2):317-27.
  14. Strange C, Sahn, SA. Massive hemoptysis. In Parrillo JE, Dellinger RP (eds) Critical Care Medicine: Principles of Diagnosis and Management. Mosby 2003.
  15. Strange C. Pleural diseases. In Stoller JA, Scanlan C, Wilkins R eds. Egan's Fundamentals of Respiratory Care. 8th ed. Mosby-Year Book, Inc., Chicago, 2003, 503-519.
  16. Strange C. Pleural effusions due to gastrointestinal disease. In: Light RW, Lee YCG. Textbook of pleural diseases. Edward Arnold (Publishers) Limited, London. 2003; 32:410-418.
  17. Strange C. Pneumothorax. American College of Physicians PIER. 2003. pier.acponline.org
  18. Strange C, Jantz M. Pneumothorax. In: Bouros D (ed) The Pleura. Marcel Dekker; Lung Biology in Health and Disease, Volume 186; 2004:661-676.
  19. Strange C, Highland KB. Interstitial lung disease in the patient who has connective tissue disease. Clin Chest Med 2004; 25:549-559.
  20. Huggins JT, Strange C. Pneumothorax. In: Laurent G and Shapiro S; Encyclopedia of Respiratory Medicine. Oxford, UK. Elsevier. 2006, 474-9.
  21. Strange C. Infection in the intensive care unit: A clinician's view of the role of imaging. Semin Roentgenol. 2007; 42(1):7-10.
  22. Strange C. Pleural diseases. In Stoller JA, Scanlan C, Wilkins R eds. Egan's Fundamentals of Respiratory Care. 9th ed. Mosby-Year Book, Inc., Chicago, 2009, 25: 539-554.
  23. Arakaki JSO, Strange C. Doenças Intersticiais Pulmonares e Hipertensão Pulmonar, In Gomes M, Faresin SM, ed. Pneumologia: Atualização e Reciclagem, Sétima Edição, Editora Roca LTDA, São Paulo, Brazil. 2008, 25:210-213.
  24. Strange C. Pleural effusions due to gastrointestinal disease. In: Light RW, Lee YCG. Textbook of pleural diseases. Hodder Arnold, London. 2008, 465-472.
  25. Brown AN, Strange C. Connective Tissue Disease and Vasculitis Associated Interstitial Lung Disease In Baughman RP, Carbone R. ed. Pulmonary Arterial Hypertension and Interstitial Lung Diseases: A Clinical Guide, Humana Press, New York: 2008, 159-176.
  26. Strange C. Other pleuropulmonary manifestations of connective tissue diseases. In. Lynch JP. Interstitial Pulmonary and Bronchiolar Disorders. New York. Informa Healthcare: 2008, 487-501.

27. Garwood S, Strange C, Sahn SA. Massive hemoptysis. In Parrillo JE, Dellinger RP (eds) Critical Care Medicine: Principles of Diagnosis and Management. Third Edition. Mosby 2009, in press.
28. Strange C, Janciauskiene S. Alpha-1 antitrypsin deficiency. In McCormick FX. Rare Lung Diseases, 2009, in press.

### **Collaborative Group Authorship**

1. Alpha-1-Antitrypsin Deficiency Registry Study Group. A registry of patients with severe deficiency of alpha-1-antitrypsin: Design and Methods. Chest 1994; 106:1223-32.
2. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R, Pennington J, Wherry JC for the TNF- $\alpha$  MAb Sepsis Study Group. Efficacy and safety of monoclonal antibody to human tumor necrosis factor  $\alpha$  in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial. JAMA. 1995, 273:934-41.
3. McElvaney NG, Stoller JK, Buist AS, Prakash UBS, Brantley ML, Schluchter MD, Crystal RG, and the  $\alpha$ <sub>1</sub>-Antitrypsin Deficiency Registry Study Group. Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of  $\alpha$ <sub>1</sub>-antitrypsin deficiency. Chest 1997; 111:394-403.
4. Turino GM, Barker AF, Brantley ML, Cohen AB, Connelly RP, Crystal RG, Eden E, Schluchter MD, Stoller JK for the Alpha-1-Antitrypsin Deficiency Registry Study Group. Clinical features of individuals with PI\*SZ phenotype of  $\alpha$ <sub>1</sub>-antitrypsin deficiency. Am Rev Respir Crit Care Med 1996; 154:1718-25.
5. Stoller JK, Buist AS, Burrows B, Crystal RG, Fallat RJ, McCarthy K, Schluchter MD, Soskel NT, Zhang R, and the  $\alpha$ <sub>1</sub>-Antitrypsin Deficiency Registry Study Group. Quality control of spirometric testing in the registry for patients with severe  $\alpha$ <sub>1</sub>-Antitrypsin Deficiency. Chest 1997; 111:899-909.
6. Opal SM, Fisher CJ, Dhainaut JFA, Vincent JL, Brase R, Lowry SF, Sadoff JC, Slotman GJ, Levy H, Balk RA, Shelly MP, Pribble JP, LaBrecque JF, Lookbaugh J, Donovan H, Dubin H, Baughman R, Norman J, DeMaria E, Matzel K, Abraham E, Seneff M, and the Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial Crit Care Med 1997; 25:1115-24.
7. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of alpha-1-antitrypsin. Am J Respir Crit Care Med 1998; 158:49-59.
8. The ACCESS Research Group. Design of a case control etiologic study of sarcoidosis (ACCESS). J Clin Epidemiology. 1999, 52(12):1173-86.
9. Esteban A, Anzueto A, Alia I, Gordo G, Apezteguia C, Palizas F, Cide D, Goldwasser R, Soto L, Bugedo G, Rodrigo C, Pimentel J, Raimondi G, Tobin MJ for the Mechanical Ventilation International Study Group. How is mechanical ventilation employed in the intensive care unit? An international utilization review. Am J Respir Crit Care Med 2000; 161:1450-8.
10. Stoller JK, Brantley M, Fleming LE, Bean JA, Walsh J for the Alpha One Foundation Research Network Registry Investigators. Formation and current results of a patient-organized registry for  $\alpha$ <sub>1</sub>-antitrypsin deficiency. Chest 2000, 118:843-8.
11. Abraham E, Laterre PF, Garbino J, Pingleton S, Butler T, Dugernier T, Margolis B, Kudsk K, Zimmerli W, Anderson P, Reynaert M, Lew D, Lesslauer W, Cooper P, Burdeska A, Passe S, Modi M, Leighton A, Salgo M, Van der Auwera P, for the Tenefuse® Study Group. Lenercept (p55-Tumor Necrosis Factor Receptor Fusion Protein) in severe sepsis and early septic shock. A randomized double blind placebo-controlled multicenter phase III trial with 1342 patients. Crit Care Med 2001, 29(3):503-10.
12. Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H, Bresnitz EA, DePalo L, Hunninghake G, Iannuzzi MC, Johns CJ, McLennan G, Moller DR, Newman LS, Rabin DL, Rose C, Rybicki B, Weinberger SE, Terrin ML, Knatterud GL, Cherniak R; A Case Control Etiologic Study of Sarcoidosis (ACCESS) research group. Clinical Characteristics of Patients in a Case Control Study of Sarcoidosis. Am J Respir Crit Care Med 2001; 164:1885-9.
13. Rybicki BA, Iannuzzi MC, Frederick MM, Thompson BW, Rossman MD, Bresnitz EA, Terrin ML, Moller DR, Barnard J, Baughman RP, DePalo L, Hunninghake G, Johns C, Judson MA, Knatterud GL, McLennan

- G, Newman LS, Rabin DL, Rose C, Teirstein AS, Weinberger SE, Yeager H, Cherniack R; The ACCESS Research Group. Familial aggregation of sarcoidosis. a case-control etiologic study of sarcoidosis (ACCESS). *Am J Respir Crit Care Med* 2001; 164:2085-91.
14. Esteban A, Anzueto A, Frutos F, Alia I, Brochard L, Stewart TE, Benito S, Epstein SK, Apezteguia C, Nightingale P, Arroliga AC, Tobin MJ, Mechanical Ventilation International Study Group. Characteristics and outcomes in adult patients receiving mechanical ventilation: a 28 day international study. *JAMA* 2002; 287:345-55.
  15. Judson MA, Thompson BW, Rabin DL, Steimel J, Knatterud GL, Lackland DT, Rose C, Rand CS, Baughman RP, Teirstein AS; ACCESS Research Group. The diagnostic pathway to sarcoidosis. *Chest* 2003, 123:406-12.
  16. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, Light B, Spapen H, Stone J, Seibert A, Peckelsen C, De Deyne C, Postier R, Pettila V, Artigas A, Percell SR, Shu V, Zwingerstein C, Tobias J, Poole L, Stolzenbach JC, Creasey AA; OPTIMIST Trial Study Group. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. *JAMA*. 2003; 290:238-47.
  17. Rossman MD, Thompson B, Frederick M, Maliarik M, Iannuzzi MC, Rybicki BA, Pandey JP, Newman LS, Magira E, Beznik-Cizman B, Monos D, The ACCESS Group. HLA-DRB1\*1101: A significant risk factor for sarcoidosis in blacks and whites. *Am J Hum Genet* 2003; 73:720-35.
  18. Judson MA, Baughman RP, Thompson BW, Teirstein AS, Terri ML, Rossman MD, Yeager H, McLennan G, Bresnitz EA, DePalo L, Hunninghake G, Iannuzzi MC, Johns CJ, Moller DR, Newman LS, Rabin DL, Rose C, Rybicki BA, Weinberger SE, Knatterud GL, Cherniack R, and ACCESS Research Group. Two year prognosis of sarcoidosis: the ACCESS experience. *Sarcoidosis vasculitis and diffuse lung diseases* 2003;20:204-211.
  19. Bakker J, Gover R, McLuckie A, Holzqapfel L, Andersson J, Lodato R, Watson D, Grossman S, Donaldson J, Takala J, on behalf of the Glaxo Wellcome International Septic Shock Study Group. Administration of the nitric oxide synthase inhibitor N<sup>G</sup>-methyl-L arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patient with severe sepsis: Results of a randomized, double-blind, placebo-controlled multicenter study (study no.144-002). *Crit Care Med* 2004; 32:1-11.
  20. Watson D, Grover R, Anzueto A, Lorente J, Smithies M, Bellomo R, Guntupalli K, Grossman S, Donaldson J, Le Gall JR, on behalf of the Glaxo Wellcome International Septic Shock Study Group. Cardiovascular effects of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) in patients with septic shock: Result of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002) *Crit Care Med* 2004; 32:13-20.
  21. Lopez A, Lorente A, Steingrub J, Bakker J, McLuckie A, Willatts S, Brockway M, Anzueto A, Holzqapfel L, Breen D, Silverman MS, Takala J, Donaldson J, Arneson C, Grove G, Grossman S, Grover R on behalf of the Glaxo Wellcome International Septic Shock Study Group. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. *Crit Care Med* 2004;32:21-30.
  22. Newman LS, Rose CS, Bresnitz EA, Rossman MD, Barnard J, Frederick M, Terrin ML, Weinberger SE, Moller DR, McLennan G, Hunninghake G, DePalo L, Baughman RP, Iannuzzi MC, Judson MA, Knatterud GL, Thompson BW, Teirstein AS, Yeager H Jr, Johns CJ, Rabin DL, Rybicki BA, Cherniack R, and the ACCESS Research Group. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. *Am J Respir Crit Care Med* 2004; 170:1324-30.
  23. Esteban A, Anzueto A, Frutos-Vivar F, Alia I, Ely EW, Brochard L, Stewart TE, Apezteguia C, Tobin MJ, Nightingale P, Matamis D, Pimentel J, Abroug F. Mechanical Ventilation International Study Group. Outcome of older patients receiving mechanical ventilation. *Intensive Care Med* 2004; 30:639-46.
  24. Anzueto A, Frutos-Vivar F, Esteban A, Alia I, Brochard L, Stewart T, Benito S, Tobin MJ, Elizalde J, Palizas F, David CM, Pimentel J, Gonzalez M, Soto L, D'Empaire G, Pelosi P. Mechanical Ventilation International Study Group. Incidence, risk factors and outcome of barotrauma in mechanically ventilated patients

- Intensive Care Med (2004) 30:612–619.
25. Barnard J, Rose C NewmanL, Canner M, Martyn J, McCammon C, Bresnitz E, Rossman M, Thompson B, Tybicki B, Weinberger SE, Moller DR, McLennan G, Hunninghake G, DePalo L, Baughman RP, Iannuzzi MC, Judson MA, Knatterud GL, Teirstein AS, Yeager H Jr, Johns CJ, Rabin DL, Cherniack R, and the ACCESS Research Group. Job and industry classifications associated with sarcoidosis in A Case-Control Etiologic Study of Sarcoidosis (ACCESS). *J Occup Environ Med* 2005; 47:226-34.
  26. Teirstein AS, Judson MA, Baughman RP, Rossman MD, Yeager H Jr, Moller DR, A Case Control Etiologic Study of Sarcoidosis (ACCESS) Writing Group. The spectrum of biopsy sites for the diagnosis of sarcoidosis. *Sarcoidosis Vasc Diffuse Lung Dis* 2005; 22:139-46.
  27. Yeager H, Rossman MD, Baughman RP, Teirstein AS, Judson MA, Rabin DL, Iannuzzi MC, Rose C Bresnitz EA, DePalo L, Hunninghake G, Johns CJ, McLennan G, Moller DR, Newman LS, Rybicki B, Weinberger SE, Wilkins PC, Cherniack R, ACCESS Research Group. Pulmonary and psychosocial findings at enrollment in the ACCESS study. *Sarcoidosis Vasc Diffuse Lung Dis* 2005; 22:147-53.
  28. Tejerina E, Frutos-Vivar F, Restrepo MI, Anzueto A, Fernando Palizas MDc, González M, Apezteguía C, Abroug F, Matamis D, Bugedo G, Andre's Esteban A. for the International Mechanical Ventilation Study Group. Prognosis factors and outcome of community-acquired pneumonia needing mechanical ventilation. *J Crit Care* 2005;20(3):230.
  29. Frutos-Vivar F, Esteban A, Apezteguía C, Anzueto A, Nightingale P, González M, Soto L, Rodrigo C, Raad J, David CM, Matamis M, D'Empaire G, for the International Mechanical Ventilation Study Group. Outcome of mechanically ventilated patients who require a tracheostomy. *Crit Care Med* 2005; 33:290-298.
  30. Ferguson ND, Frutos-Vivar F, Esteban A, Anzueto A, Alía I, Brower RG, Stewart TE, Apezteguía C, González M, Soto L, Abroug F, Brochard L, for the Mechanical Ventilation International Study Group. Airway pressures, tidal volumes, and mortality in patients with acute respiratory distress syndrome. *Crit Care Med* 2005, 33:21-30.
  31. Arroliga A, Frutos-Vivar F, Hall J, Esteban A, Apezteguia C, Sota L, Anzueta A, for the International Mechanical Ventilation Study Group. Use of sedative and neuromuscular blockers in a cohort of patients receiving mechanical ventilation. *Chest* 2005; 128:496-506.
  32. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, François B, Guy JS, Brückmann M, Rea-Neto Á, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL, for the ADDRESS Study Group. Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of Death. *N Engl J Med* 2005; 353:1332-41.
  33. Khanna D, Clements PJ, Furst DE, Chon Y, Elashoff R, Roth MD, Sterz M, Chung J, FitzGerald JD, Seibold JR, Varga J, Theodore A, Wigley F, Silver RM, Steen V, Mayes M, Connolly K, Fessler BJ, Rothfield N, Mubarak K, Molitor J, Tashkin DP, for the Scleroderma Lung Study Group. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. *Arthritis Rheum* 2005; 52(2):592-600.
  34. Tejerina E, Frutos-Vivar F, Restrepo MI, Anzueto A, Abroug F, Palizas F, González M, D'Empaire G, Apezteguía C, Esteban A, for the Internacional Mechanical Ventilation Study Group. Incidence, risk factors and outcome of ventilator-associated pneumonia. *J Crit Care* 2006,21(1):56-65.
  35. Frutos-Vivar F, Esteban A, Anzueto A, Apezteguia C, González M, Bugedo G, D'Empaire G, Palizas F, Elizalde J, Soto L, David CM, RodrigoC para el International Study Mechanical Ventilation Group. Pronostico de los enfermos con enfermedad pulmonar obstructiva cronica reagudizada que precisan ventilacion mecanica. *Medicina Intensiva* 2006, 30(2):52-61.
  36. Cole JC, Khanna D, Clements PJ, Seibold JR, Tashkin DP, Paulus HE, Irwin MR, Motivala SJ, Furst DE on behalf of the Scleroderma Lung Study (SLS) and Relaxin Study. Single-factor scoring validation for the Health Assessment Questionnaire-Disability Index (HAQ-DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patients. *Qual Life Res.* 2006 Oct 31, 15(8):1355-1371.

37. Distler O, Behrens F, Pittrow D, Huscher D, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibold JR, Furst DE for the other coauthors of the EPOSS-OMERACT group. Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: Delphi consensus study with cluster analysis. *Arthritis Care & Research* 2008, 59(6):867-75. PMID: 18512721
38. Goldin JG, Lynch DA, Stollo DC, Suh RD, Schraufnagel DE, Clements PJ, Elashoff RM, Furst DE, Vasunilashorn S, McNitt-Gray MF, Brown MS, Roth MD, Tashkin DP; Scleroderma Lung Study Research Group. High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. *Chest*. 2008 Aug;134(2):358-67. Epub 2008 Jul 18. PMID: 18641099

### **Non- Refereed Publications**

1. Strange C. Massive hemoptysis. *Pulmonary and Critical Care Update* 1990; 5(19):1-7.
2. Lemense G, Strange C. Refractory hypotension in a patient on coumadin. *Hospital Practice* 1994; 29(3):121-4.
3. Keys T, Strange C. Corticosteroids in ARDS: prevention and treatment. *Pulmonary and Critical Care Update*, 1993; 9 (6): 1-8.
4. Joseph J, Strange C, Sahn SA. Letter to the editor: Identifying *Pneumocystis carinii* in pleural effusions. *Ann Intern Med* 1993, 119:1222.5.
5. Strange C. A patient with thrombocytopenia and renal failure. In Sahn SA, Heffner JE (eds) *Critical Care Pearls*, second edition, Hanley and Belfus, Inc. 1997, 60-62.
6. Baumann M, Strange C. Treatment of spontaneous pneumothorax. Letter to the editor. *Chest* 1998, 1424-1425.
7. Strange C. Empiricism in medicine: therapy of respiratory tract infections. *J Infectious Disease Pharmacotherapy* 1999, 3:9-16.
8. Strange C. Spontaneous pneumothorax: tips on the timing of chest tube removal. *J Respir Dis* 1999, 20(5):339.
9. Ferro TJ, DeBellis RJ, Flume PA, Ramirez JA, Schwartz DB, Strange C, Teba L. Prudent antibiotic treatment and responsibility in outpatient management today: Curing the patient today, protecting the community for tomorrow. *Infectious Diseases in Clinical Practice*. 2003; 12(1S):1-4.
10. Loveland SM, Lewin JJ, Amabile CM, Strange C, Mazur JE. Obese man treated with drotrecogin alfa (activated). *Ann Pharmacother* 2003, 37:918-9.
11. Mazur J, Strange C. Letter to the editor: Reply: Obese man treated with drotrecogin alpha (activated). *Ann Pharmacother*, 2004; 38:722-23.
12. Strange C. Idiopathic Pulmonary Fibrosis: A systematic approach to diagnosis. CME monograph. August 2004, Dannemiller Memorial Educational Foundation and the France Foundation.
13. Strange C. Exercise testing for interstitial lung disease. Winter 2005 Pilot Monograph. The France Foundation.
14. Strange C, Mohr L, Simpson W. Smoking and farming: issues in lung health. *National Rural Health Association Newsletter*, Winter 2006.
15. Strange C, Stoller JK, editor, AATD Update: Chronic disease reduction through early detection and diagnosis. *Discovery Institute of Medical Education*, Volume 1 Issue 2, February 2007.
16. Clayton SB, Strange C. Hypoglycemia risk: A cause for concern in the intensive care unit hyperglycemia control debate. *Crit Care Med*. 2007 Apr;35(4):1222-e11.
17. Strange C, Bolster M, Roth M. BAL in Scleroderma, Letter to the Editor, *Am J Respir Crit Care Med* 2008, 177 (11):1293.
18. Seibold J, Strange C. Scleroderma lung disease- "If you don't know where you are going any road will get you there". *Am J Respir Crit Care Med* 2008; 177 (11):1178-9. PMID: 18487619
19. McLaughlin V, Strange C. Opportunities and Challenges in the Study of Pulmonary Arterial Hypertension. *Am J Respir Crit Care Med* 2009; 179(2):91-2. PMID: 19119151
20. Strange C. Alpha-1 Antitrypsin Deficiency. *Pulmonary Perspectives*, American College of Chest Physicians, 2009.

**Electronic Publications**

1. Up To Date in Pulmonary Medicine: Parapneumonic pleural effusions and empyema 2003-Present with yearly updates.
2. PIER, American Board of Internal Medicine: Hemoptysis 2003-2005.